According to a recent Lex Machina report, the number of Abbreviated New Drug Application (ANDA) patent litigation filings increased 68% from 2014-2015. In the five years prior, an average of 269 cases were filed each year, but from 2014-2015, the average rose to 451 cases. In the report, Finnegan is cited as one of the top firms filing ANDA lawsuits on behalf of plaintiffs with 274 cases. While ANDA cases only make up approximately 10 percent of all patent filings, this increase is a sign that things are becoming intense in the pharmaceutical industry.
Press Release
September 11, 2024
Announcement
September 3, 2024
Announcement
Finnegan and Partner Daniel Chung Recognized by The National Law Journal
September 3, 2024
Press Release
Finnegan Named a “True Trailblazer” for Its Continued Commitment to Mansfield Certification Process
August 16, 2024
Due to international data regulations, we’ve updated our privacy policy. Click here to read our privacy policy in full.
We use cookies on this website to provide you with the best user experience. By accepting cookies, you agree to our use of cookies. Please note that if you opt not to accept or if you disable cookies, the “Your Finnegan” feature on this website will be disabled as well. For more information on how we use cookies, please see our Privacy Policy.
Finnegan is thrilled to announce the launch of our new blog, Ad Law Buzz, devoted solely to breaking news, developments, trends, and analysis in advertising law.